Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allergan/Richter’s Antipsychotic Vraylar Offers New Mechanism Of Action

This article was originally published in The Pink Sheet Daily

Executive Summary

Schizophrenia and bipolar disorder treatment will launch in first quarter of 2016.


Related Content

Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA
Allergan Confident Data Support Bipolar Depression Addition To Vraylar's Label
Allergan Hopes To Add Bipolar Depression To Vraylar's Label
Allergan Seeks Quick Vraylar Turnaround After US FDA Refuses To File
Allergan Urgently Seeks FDA Guidance To Unblock Vraylar sNDA Review
Uphill Climb For Gedeon Richter's Cariprazine After Delayed EU OK


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts